eosinophilic respiratory problems: allergic bronchopulmonary aspergillosis
DESCRIPTION
Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis. Paul A. Greenberger, M.D. 6 December 2011 Workshop 12. Objectives. To review the differential diagnosis of pulmonary eosinophilia in patients with asthma - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/1.jpg)
Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis
Paul A. Greenberger, M.D.6 December 2011
Workshop 12
![Page 2: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/2.jpg)
Objectives
• To review the differential diagnosis of pulmonary eosinophilia in patients with asthma
• To discuss classification of Allergic Bronchopulmonary Aspergillosis (ABPA)
• To consider treatment options for ABPA-corticosteroids, anti-fungals, and immunomodulators
![Page 3: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/3.jpg)
Minimal Diagnostic Criteria for ABPA-Central Bronchiectasis (ABPA-CB)
• Asthma• Central bronchiectasis• Immediate cutaneous reactivity to Aspergillus
species or A. fumigatus• Elevated total serum IgE (>417 kU/L)• Elevated serum IgE-A.fumigatus and or IgG-
A.fumigatus compared to sera from prick positive patients with asthma
![Page 4: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/4.jpg)
Populations at Risk of ABPA
• Asthma, mild intermittent to persistent severe asthma-about 1% of persistent asthma patients – diagnosed before age 20 but can be found in children and even geriatric patients. (Dx may be overlooked for decades)
• Cystic Fibrosis- from 1-14% in literature; ABPA may worsen the course of CF (air trapping, airway narrowing, unequal ventilation)
![Page 5: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/5.jpg)
The Genus Aspergillus Has Over 180 Species
• There are 22 recognized recombinant Aspergillus allergens by the IUIS designated Asp f 1 to Asp f 29. Molecular weights 11-90 kD.
• Four of the 22 include 2 from A. niger and 1 from A. oryzae and 1 from A. flavus.
• Approximately 40 components of A. fumigatus bind to IgE antibodies.
![Page 6: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/6.jpg)
A. fumigatus- Characteristics
• Ubiquitous-outdoor recoveries even in winter• Thermotolerant• High numbers of spores occur after exposure
to moldy hay, compost piles, potting soil, moldy wood chips, decaying vegetation, crawl spaces and basements, etc
![Page 7: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/7.jpg)
![Page 8: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/8.jpg)
Question: What fungi grow in bird droppings?
• ___________________• ___________________• ___________________• ___________________
![Page 9: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/9.jpg)
In The Indoor Environment, Aspergillus fumigatus Can Be Recovered In/From
• Bedrooms Yes No ?• Hallways Yes No ?• Bathrooms Yes No ?• Water supply Yes No ?
![Page 10: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/10.jpg)
Normal Defenses Against Inhaled A. fumigatus Spores
• Alveolar macrophages-ingest and kill spores• PMNs-kill by an oxidative burst• Pulmonary epithelium-as a barrier• Alternative pathway of Complement-C3 and
C5• Platelets
![Page 11: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/11.jpg)
Presentation of ABPA
• Asymptomatic pulmonary infiltrate• Pulmonary infiltrate(s) with eosinophilia• Worsening asthma• Peripheral blood eosinophilia• Inspisated mucus difficult to remove during
bronchoscopy..• Minimal cough or wheeze (or no asthma)
![Page 12: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/12.jpg)
Complications of ABPA
• End Stage fibro-cavitary lung disease-Pseudomonas pneumonias, chronic sputum production, home O2
• Deaths, lung transplants• Worsening of asthma from mild to prednisone
dependent
![Page 13: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/13.jpg)
Obejctive 1: Differential Diagnosis• Asthma with middle lobe
syndrome• Severe asthma with fungal sensitization (SAFS)• Asthma with community
acquired pneumonia• Chronic eosinophilic
pneumonia• Churg-Strauss Syndrome• Mucoid impaction syndrome• ABPMycosis
• Bronchocentric granulomatosis
• Hyper IgE Syndrome• Chronic Granulomatous
Disease• Parasitism (Ascaris,
Strongyloides etc) • Cystic Fibrosis• Idiopathic Bronchiectasis
![Page 14: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/14.jpg)
Randomized Controlled Trial of Oral AntifungalTreatment for Severe Asthma with Fungal Sensitization
The Fungal Asthma Sensitization Trial (FAST) Study• AJRCCM 2009;179:11-18• Patients with SAFS do not fulfill criteria for ABPA
• Criteria for SAFS….• 1. severe (poorly controlled) asthma, 2. total IgE concentration < 1000 IU/mL (< 1000 kU/L) 3. skin test + or elevated in vitro IgE to ANY fungus
![Page 15: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/15.jpg)
Objective 2. Classification of ABPA
![Page 16: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/16.jpg)
![Page 17: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/17.jpg)
Stages---- Radiographic Findings----Total IgE
1. Acute Upper or middle Sharply elevated
2. Remission No infiltrate and no pred > 6 mon
Elevated or normal
3. Exacerbation Upper or middle Sharply elevated
4. Corticosteroid dependent asthma
Often without infiltrates, but can have PIE
Elevated or normal
5. End Stage Fibrotic, bullous or cavitary
Might be normal
![Page 18: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/18.jpg)
Two Categories of ABPA
• ABPA-Central Bronchiectasis (ABPA-CB) with bronchiectasis present on inner 2/3 of CT field
• ABPA-Seropositive (ABPA-S)-which is a less aggressive form (Ann Allergy 1993;70:333-338)
• ABPA-S can convert to ABPA-CB
![Page 19: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/19.jpg)
Classification of ABPA
• ABPA with central bronchiectasis …..ABPA-CB• ABPA without bronchiectasis………….ABPA-S• ABPA with “other radiologic findings”..ABPA-ORF
• ABPA is classified into 5 stages for ABPA-CB and 4 stages for ABPA-Seropositive
• Patients can change stages over time in either direction except if stage 5 (end stage- fibrocavitary)
![Page 20: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/20.jpg)
Objective 3. Treatment Options
• Oral Corticosteroids• Anti-fungals • Immunomodulators
• TREAT the ASTHMA and CO-MORBIDITIES• CONSIDER ENVIRONMENTAL SOURCES
![Page 21: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/21.jpg)
Prednisone as Monotherapy
• 0.5mg/kg/each am for 2 weeks then on alterate mornings for 2 months….then
• Taper prednisone• Repeat HRCT examination• Repeat total IgE (should decline at least by
33%)• Environmental exposures to molds-inquire re
home and workplace for obvious sources
![Page 22: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/22.jpg)
Antifungals
• Oral (itraconazole, voriconazole, posaconazole)• Adverse effects of itraconazole…Gastrointestinal
intolerance, LFTs, headache, peripheral neuropathy, sleep disturbance….and inhibition of CYP 3A4 dependent hepatic metabolism (increases concentration of prednisolone (not prednisone) and inhaled budesonide and fluticasone causing HPA suppression)
![Page 23: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/23.jpg)
Itraconazole is a POTENT INHIBITOR of medications metabolized via CYP3A4
• Potentiation of budesonide 400 ug/day in 2 weeks leading to adrenal suppression (J Cyst Fibrosis 2003;2: 73-5)
• Methylprednisolone• Statins• Cyclosporine
![Page 24: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/24.jpg)
Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: A
randomized controlled trialJACI 2003;111:952-7
• Itraconazole 400 mg daily for 16 weeks• Primary outcome was induced sputum eos• Secondary outcome measures: TEC, total IgE
concentration, IgE-A fumigatus by CAP• No pt had a change in LFTs• Baseline FEV1 % = 55 (itraconazole) and 52
(placebo)
![Page 25: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/25.jpg)
Outcomes
• Induced sputum eos: 3.8% decreased to 0.4% vs 3.0 to about 2% in controls
• Sputum ECP 4900 ng/ml decreased to 3000 in 4 weeks vs 3400 increased to 3600 in controls
• Thus, sputum eos are reduced with itraconazole; sputum ECP follows suit
![Page 26: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/26.jpg)
Clinical Markers
• Asthma exacerbations: 0 if itraconazole vs 1.5 for controls over 16 weeks
• No improvement in FEV1• Conclusions: There are reductions in AIRWAY
INFLAMMATION (induced sputum eos and sputum ECP) with itraconazole
![Page 27: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/27.jpg)
Voriconazole
• Improved oral bioavailability than itraconazole• Peripheral blood concentrations
have……….100 fold interpatient variability vs 15 fold with itraconazole!
• Adverse effects of hepatic, ophthalmologic, photosensitivity
• Dosage in adults <65 yrs is 200mg bid
![Page 28: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/28.jpg)
VORICONAZOLE THERAPY IN CHILDREN WITH CYSTIC FIBROSIS
J Cyst Fibrosis 2005;4:215-20
• 21 CF children (ages 5-16 yrs)• Monotherapy in 2 children, sustained improvement
for 13 months• Combined with steroids in 11 children with
improvement• Monotherapy in Af colonized, non-ABPA pts-no
change in symptoms• Adverse effects: 7 (33%) including photosensitivity,
nausea, LFTs, alopecia
![Page 29: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/29.jpg)
Question: The T ½ of Serum IgE is
• 6 days• 5 days• 23 days• 2.3 days• 14-21 days
![Page 30: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/30.jpg)
Omalizumab
• Case reports (some +, some -)• Controlled trial for CF-ABPA initiated
![Page 31: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/31.jpg)
Omalizumab (Thorax 2007;62:276-7)
![Page 32: Eosinophilic Respiratory Problems: Allergic Bronchopulmonary Aspergillosis](https://reader035.vdocuments.site/reader035/viewer/2022062314/56813fe4550346895daacf56/html5/thumbnails/32.jpg)
Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis
AllergyVolume 65, Issue 1, pages 134-135, 5 OCT 2009 DOI: 10.1111/j.1398-9995.2009.02147.xhttp://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2009.02147.x/full#f1